We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CEPI to Fund Late-Stage COVID-19 Vaccine Trial From Clover Biopharmaceuticals
CEPI to Fund Late-Stage COVID-19 Vaccine Trial From Clover Biopharmaceuticals
The Coalition for Epidemic Preparedness Innovations (CEPI) has agreed to fund development of a potential COVID-19 vaccine from China’s Clover Biopharmaceuticals with a global phase 2/3 study and through licensing and distribution.